Abstract:Integrin aVb3 is a prominent member of the "RGD-recognizing" integrin family of cell surface receptors. aVb3 binds to various extracellular matrix (ECM) proteins and oxysterols such as 25-hydroxycholesterol, is implicated in several diseases, including cancer metastasis, lung fibrosis, inflammation, and autoimmune diseases, and is pursued as a valuable therapeutic target. Despite enormous efforts to seek a pure antagonist, to date, no single drug candidate has successfully reached clinics due to associated partial agonism and toxicity issues. Developing effective and safe inhibitors require a thorough understanding of the molecular interactions and structural changes related to the receptor's activation and inhibition mechanisms. This study offers a comprehensive residue-residue contact and network analyses of the ligand-binding beta-propeller alpha-I domains (headpiece) based on all available experimental structures of integrin aVb3 in unliganded, agonist-, antagonist-, and antibody-bound states. The analyses reveal many critical interactions that were not reported before and show that specific orientation and interactions of residues from the specificity-determining loop (SDL) are critical in molecular recognition and regulation. Also, the network analysis reveals that residues from the nearby allosteric site (site II) connect to the primary RGD-binding site via SDL, which likely acts as an interface between the two sites. Our results provide valuable insights into molecular interactions, structural changes, distinct features of the active and inactive headpiece conformations, the role of SDL in ligand recognition, and SDL-mediated allostery. Thus, the insights from this study may facilitate the designing of pure antagonists or site II-mediated allosteric modulators to integrin aVb3 to treat various diseases.

Role of RGD in Integrin and Fibronecin Mediated Biological Process

An RGD-Containing Peptide Derived from Wild Silkworm Silk Fibroin Promotes Cell Adhesion and Spreading

Molecular basis for the targeted binding of RGD-containing peptide to integrin αVβ3.

Molecular Basis For The Targeted Binding Of Rgd-Containing Peptide To Integrin Alpha(V)Beta(3)

Application of RGD Ligands Targeting Integrin α_vβ_3 in Anti-tumor Angiogenesis

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions

Interaction Mechanism and Clustering among Rgd Peptides and Integrins

RGD cadherins and α2β1 integrin in cancer metastasis: A dangerous liaison

Interaction Between Integrin Alpha(Iib)Beta(3) and Synthesized Cyclic Hexapeptide Containing Rgd

Interaction between integrin α IIb β 3 and synthesized cyclic hexapeptide containing RGD

Function and Mechanism of RGD in Bone and Cartilage Tissue Engineering

Activation of human T lymphocytes via integrin signaling induced by RGD-disintegrins

Structural insights into the molecular recognition of integrin αVβ3 by RGD-containing ligands: The role of the specificity-determining loop (SDL)

Comparison of Linear Vs. Cyclic RGD Pentapeptide Interactions with Integrin Αvβ3 by Molecular Dynamics Simulations

Integrins as Receptors for Extracellular Matrix

Extracellular vesicle mobility in collagen I hydrogels is modulated by RGD-binding integrins

Research Progress on the Relationship Between Integrin and Angiogenesis

An RGD motif present in cadherin 17 induces integrin activation and tumor growth

Recent progress in biomedical applications of RGD-based ligand: From precise cancer theranostics to biomaterial engineering: A systematic review

Effect of amino acids near the RGD sequence on binding activities between αIIbβ3 integrin and fibrinogen in the presence of RGD-containing synthetic peptides from elegantin and angustatin

Integrin α v β 3 targeting activity study of different retro-inverso sequences of RGD and their potentiality in the designing of tumor targeting peptides